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INVITED CLINICAL REVIEW
Peripheral vascular brachytherapy
Anton N. Sidawy, MD, MPH,a Jonathan M. Weiswasser, MD,a and Ron Waksman, MD,b
Washington, DC
Ongoing advances in peripheral endovascular technology have been met with disappointing results because of restenosis
within the treated vessel. In particular, stent balloon angioplasty of peripheral vessels has yet to achieve patency rates that
approximate conventional treatment in the long term. Recent advances in stent, balloon, and wire construction include
the incorporation of radioactive substances in an attempt to ameliorate the inflammatory response provoked by typical
endovascular manipulation, a technique termed vascular brachytherapy. - and -isotopes and external beam radiation
target the very cell population whose activity results in the development of neointimal hyperplasia. Although most clinical
research examining the efficacy of vascular brachytherapy has emerged from the coronary artery literature, the use of
vascular brachytherapy also has been examined in the peripheral arterial tree and has shown promising results. Current
data indicate that vascular brachytherapy is a safe and accessible adjunctive endovascular maneuver that may improve the
short-term patency rate of peripheral endovascular applications. The effects on long-term patency rates remain indeter-
minate compared to conventional therapy. (J Vasc Surg 2002;35:1041-7.)
As technology advances the treatment of vascular dis-
ease, it is clear that the limits of many endovascular inter-
ventions are defined by the development of restenosis in
treated vessels. Although most data on this subject have
been gleaned from work performed on coronary vessels,
recent data on peripheral arteries have illustrated the pre-
dictable similarity between the two arterial beds, most
notably the mechanisms for disease formation and resteno-
sis after manipulation.
Currently, endovascular treatment of infrainguinal dis-
ease, for example, consists mainly of percutaneous translu-
minal angioplasty (PTA) and stent balloon angioplasty
(SBA). Although these methods have yielded encouraging
results, with 5-year clinical success rates ranging from 42%
to 58%,1,2 they have yet to match or supercede surgical
methods in most cases. SBA has the added promise of a
mechanical scaffold to encourage patency; however, it has
produced 5-year patency rates in the 20% to 50% range,3,4
which are encouraging results but not comparable with
those of surgical bypass procedures in the infrainguinal
position. These results lay truth to the claim that SBA does
not provide any additional benefit to PTA in infrainguinal
disease and that PTA itself should be reserved for specific
short segment stenoses in patients unable to tolerate an
open procedure for limb salvage.
These results, especially with progression distally into
the arterial tree, are attributable to the development of
restenosis and reocclusion of the vessel, mostly through the
development of neointimal hyperplasia. It is this process
that arterial brachytherapy attempts to address.
MECHANISMS OF RESTENOSIS
Three mechanisms are responsible for the development
of restenosis: elastic recoil, intimal hyperplasia, and late
vascular constriction, all grouped under the catch phrase
“negative remodeling.”5-7 In the peripheral system, reste-
nosis is seen mainly in small-sized and medium-sized arter-
ies. Whereas manipulations in larger arteries, such as the
iliac system, yield patency rates that are much more prom-
ising, manipulations in smaller vessels are plagued by lesion
length, degree of stenosis, plaque burden, vessel size, and
proximal and distal flow, all factors that seem to contribute
to restenosis.
The development of elastic recoil is contingent on the
elastin fibers prevalent in the substance of the arterial wall
and the ability of these fibers to morphologically alter the
caliber of the artery. This effect is observed shortly after
injury (manipulation) of the vessel and may be theoretically
ameliorated with placement of an intraluminal scaffolding
(stent). Neointimal hyperplasia and vascular constriction
are prominent remodeling mechanisms that affect long-
term outcome and parallel mechanisms observed in wound
healing elsewhere in the body. Negative remodeling results
if this hyperplasia leads to significant luminal stenosis.
Many have investigated the cellular and inflammatory
mechanisms that lead to the development of late phase
stenosis. As it relates to vascular brachytherapy, this is the
phenomenon and target cell population that arterial irradi-
ation attempts to modulate. Strong support exists for
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monocyte-derived macrophages as pivotal in the develop-
ment of restenosis. The endothelial injury sustained in the
deployment of a stent or remodeling from angioplasty
elicits the expression of chemokines (interleukin-6, plate-
let-derived growth factor [PDGF], tumor necrosing factor-
). These chemokines attract macrophages and T cells in a
manner similar to the sequestration after the development
of an atherosclerotic plaque and typical of the response of
the surrounding adventitia to endothelial injury. Sequestra-
tion of inflammatory cells begins in either the endothelium
of the vasa vasorum or the luminal lining of endothelial cells
and is observed over a longer time course with the implan-
tation of a stent, which provides continuous stimulation of
the inflammatory cascade. The ultimate development of
neointimal hyperplasia is thought to be the result of the
direct effects of the monocyte/macrophage system or sur-
rounding endothelium through stimulatory mechanisms or
of the development and differentiation of myofibroblasts
with the inflammatory process, primarily through stimula-
tion of macrophages with PDGF and interleukin-6 and the
stimulation of smooth muscle cells with PDGF and trans-
forming growth factor.8-11 Although these mechanisms
contribute to the failure of PTA or SBA, the development
of elastic recoil affects short-term patency and technical
success, whereas neointimal hyperplasia and contracture
alter longer term outcome.
BASIC RADIOTHERAPY
Radiation physics and the effect of ionizing radiation
on biologic tissues has been a subject of study since its
discovery in the early 20th century. For therapeutic pur-
poses, radiation can be divided into two classes: -emitters
and -emitters. -Emitters emit energy in the form of
photons, high-energy electromagnetic particles, which are
generated by and originate in the nucleus, whereas -emit-
ters generate electrons from the outer orbit of unstable
elements. The energy from these emissions is absorbed by
the tissues where it has an ionizing effect, setting into
motion chemical cascades that result in terminal cellular
damage. This energy, as quantified per unit of tissue, de-
fines the dose of radiation and can be labeled as gray or rad,
where 1 Gy  100 cGy and 1 rad  1 cGy. The activity of
an isotope, the unit of which is the curie, describes a
quantity of radioactive material (1 gm of radium  1 Ci),
and the half life is the amount of time that must elapse
before only half of the original nuclei remain.
-Rays interact with tissue by imparting energy to the
tissue and setting electrons from the tissue into motion.
With -rays, a rapid decay or gradient in dose is seen as the
target acquires distance from the source, yet -rays have
high penetrating energies (20 keV to 20 MeV) so that work
with these isotopes necessitates excessive shielding. Table I
lists three major -isotopes and their physical properties.6
The only pure -emitter in clinical use is iridium-192. Its
dosimetry has been well studied, and it has a dose gradient
that makes it particularly suited to brachytherapy. Com-
pared with -emitters, the -gradient of radioactivity is
attenuated to a much lesser degree with increasing distance
from the source. With activities as high as 10 Ci, most
manipulations with typical iridium must be performed in a
radiation oncology suite because most interventional suites
have the capacity to shield only against 500 mCi.
Certain -isotopes emit both -ray and x-ray radiation,
such as iodine-125 and palladium-103. These isotopes have
lower energies and must be prescribed in much higher
activities to achieve a desired dose in an acceptable dwell
time (15 minutes). As a result, these isotopes are not
commonly encountered in vascular brachytherapy because
they are not available in activity levels that would provide
the desired dose or because they are too expensive.
-Emitters, alternatively, emit energy with release of an
unstable electron. Unlike -rays and x-rays, -rays have a
finite range in tissue that is proportional to their energy, yet
they emit higher doses per emission. Hence, the activity
necessitated to create a prescribed dose is less. This property
translates into easier shielding and handling properties.
Compared with -emitters, -emitters have a steeper en-
ergy gradient as they lose their activity more rapidly to
surrounding tissues. -Emitters have great potential for
vascular brachytherapy, especially in situations where they
can be applied in close proximity to the vessel wall. The
choice of substrate is largely determined by its half-life;
certain elements, such as copper-62, can have half-life
periods measured in minutes, whereas elements such as
strontium/yttrium 90 reach their half-life in 30 years.
VASCULAR BRACHYTHERAPY
Extensive research conducted during the last 40 years
has shown the effect that ionizing radiation has on living
tissues, most notably the direct ionization of critical struc-
tures (ie, DNA) or the indirect destruction of critical mol-
ecules subsequent to the formation of free radicals. The use
of radiation to counteract the development of abnormal
hyperplasia is well documented, as is the attenuating effect
of radiation on collagen synthesis.7 Vascular brachytherapy
is the delivery of small to moderate doses of local radiation
Table I. Major  isotopes and physical properties
Radionuclide Half-life Emission Method of production
 energy (MeV) Photon energy (MeV)
Average Maximum Average Maximum
192Ir 73.8 days Photon Neutron activation 0.18 0.67 0.37 1.06
125I 60.1 days Photon Neutron activation – – 0.028 0.035
103Pd 17.0 days Photon Neutron activation – – 0.020 0.021
Ir, Iridium; I, iodine; Pd, palladium.
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to a segment of the arterial tree in an attempt to disrupt the
development of neointimal hyperplasia or the process of
atherosclerosis. In particular, intraluminal delivery of radi-
ation after endovascular manipulation has been shown to
reduce restenosis in manipulated arteries.12-15
The paradox that a method that is implicated in the
development of vascular stenosis could be used to prophy-
lax against that very phenomenon necessitates special con-
sideration of dose and mechanism of delivery.13 Radiation
has long been known to cause vascular injury by causing
both intimal injury and stimulation and slow activation of
cells of the monocyte/macrophage lineage. Neointimal
hyperplasia shares this cell line as a precursor, which seems
to suggest that vascular brachytherapy relies on the destruc-
tion of macrophages to diminish the development of reste-
nosis. Strong laboratory evidence exists for the T cell-
derived monocyte/macrophage as the “target cell” in the
delivery of vascular radiation as a means to prevent resteno-
sis.14,15 Hence, the target cell in vascular brachytherapy
seems to be the local monocyte/macrophage system (for
the elaboration of chemokines and local growth mediators)
or the myofibroblast (the end result of the inflammatory
stimulation).
Delivery of -irradiation or -irradiation can be accom-
plished through several platforms, most of which are cath-
eter or stent based. Catheters used for delivery include line
source wires, radioactive seeds or balloons, and inflatable
systems with radioactive gas or liquid. The choice of isotope
depends on the anatomy of the vessel, the properties of the
treated lesion, and the proper identification of target tissue
that necessitates treatment. Anatomically, important pa-
rameters that also need consideration include the diameter
and the curvature of the vessel, the eccentricity of the
plaque, the lesion length, the composition of the plaque,
the amount of calcium, and the presence or absence of a
stent in the treated segment.16 Ideally, the source should
distribute radiation to only a few millimeters distance and
have a minimal dose gradient and low dose exposure to
surrounding tissues with dwell times of 15 minutes or less.
Variables such as half-life (as it pertains to multiple applica-
tions), radiation exposure to patient and operator, shield-
ing equipment, and cost are all secondary considerations.
At present, evidence supports targeting the adventitia and
the vessel wall and plaque.17,18 Currently, the American
Brachytherapy Society recommends that for peripheral ap-
plications the average luminal radius of the isotope exceed 2
mm with a dose in the range of 12 to 18 Gy.19
Ir-192, as described previously, is a pure -emitter and
is commonly used in clinical medicine. Typical Ir-192 has
activities that necessitate that it be used in heavily shielded
environments. However, Ir-192 can be generated with
lesser activities, enabling its use in the typical interventional
suite. For example, Ir-192 can be used to treat a focal
stenosis in a smaller artery with an average dwell time of 20
minutes (for a dose of more than 15 Gy) when adminis-
tered at a 2-mm radial distance from the source.
-Rays have a gradient that exposes the near wall to a
higher dose of ionizing radiation yet have a lower penetra-
tion compared with -emitters because they lose energy
rapidly and have a range of total exposure of approximately
1 cm. As described previously, -emitters appear to be a
promising source of radiation in vascular brachytherapy
because of the relatively lower exposure to nonaffected
tissue and operator and less collateral radiation within the
prescribed dwell time. Typical -emitters used in vascular
brachytherapy include rhenium-188 and rhenium-186,
which are in liquid form, and xenon-133, which is gaseous.
Phosphorus-32 is a solid -emitter used frequently.
DELIVERY SYSTEMS
Great attention has focused on delivery systems for
vascular brachytherapy. Primarily these include administra-
tion of external radiation, radioactive stents, and catheter-
based systems. External beam radiation has the advantage
of being noninvasive and the disadvantage of collateral
exposure. The most significant literature on this method is
in the treatment of arteriovenous access for dialysis, where
external beam radiation has little systemic side effects with
administration to the limb yet may have potential for re-
ducing stenoses in these grafts.20
Radioactive stents provide continuous exposure of ra-
diation through an established method of therapy. Histo-
morphologic studies in rabbit iliac arteries have confirmed
the diminutive effect on neointimal hyperplasia that stent
delivered radiation imparts.21 The primary disadvantage of
radioactive stent placement relates to the lack of homoge-
neity of delivered radiation across the stent. The geometry
of current stent design allows for certain areas to exude a
greater dose of radiation, whereas other areas may be
underserving. This phenomenon, particularly evident at the
borders of the stent, is termed “edge effect” and can result
in intimal hyperplasia in areas where dosages are minor
compared with other areas that may overdose the artery,
resulting in thrombosis or tissue necrosis. In particular, the
struts of the stent have been implicated in dose reductions
of as much as 86%,22 and further work is now focusing on
altering stent geometry to adjust the activity at the edges
and center of the stent. Attempts have recently included
construction of stents with “cold ends” but have not been
met with acceptable restenosis rates in coronary vessels.23
Catheter-based delivery systems are varied and are the
most commonly used method in clinical trials examining
the efficacy of peripheral brachytherapy. The MicroSelec-
tron-HDR (Nucletron-Odelft, The Netherlands) uses a
computerized, high dose rate afterloader, which delivers a
3-mm stepping 10 Ci in activity of Ir-192 into a centered,
closed end, segmented balloon radiation catheter (Fig).
Remote afterloading allows rapid deployment of radiation
(avoiding exposure to unaffected tissue), decreased expo-
sure to personnel, and the ability to accurately shape the
radiation dose by adjusting the source position, treatment
time, and radiation dose. The Peripheral Brachytherapy
Centering Catheter (PARIS catheter; Guidant, Santa Clara,
Calif) is a double lumen catheter with multiple centering
balloons near its tip. The design of the catheter allows for
JOURNAL OF VASCULAR SURGERY
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guidewire passage, catheter centering, and administration
of radiation.
The use of a guidewire constructed of Ir-192 intro-
duced through manual manipulation allows treatment of
short lesions in small vessels and necessitates a longer dwell
time, imparting a dose of around 500 mCi. Some have
investigated the use of an angioplasty balloon to administer
liquid (Re-188) or gas (Xe-133) phase radioactive compo-
nents to the arterial tree or even angioplasty balloons with
radioactive components.24 These -emitters allow for uni-
form dosimetry given an even proximity to the vessel wall
but carry the additional risk of possible spillage through
balloon rupture.
A novel technique was recently reported in which
polypropylene mesh was labeled with 50 mCi of tritium and
50 mCi of calcium-45 (both -emitters) and wrapped
around denuded rabbit carotid arteries. Although no ap-
preciable difference was seen in the denuded surfaces of the
experimental group compared with the control group, a
reduction was found in neointimal area, maximal intimal
thickness, and ultimate luminal stenosis. This technique
may provide an effective surgical adjunct that uses the
biology of endovascular vascular brachytherapy.25
LIMITATIONS OF BRACHYTHERAPY
Two major complications specific to vascular brachy-
therapy have emerged from the clinical trials examining this
technique: edge stenosis (or recently, radiation edge) and
late thrombosis. Late thrombosis is thought to be a delay in
intimal healing after radiation therapy and may be amelio-
rated by aspirin and or clopidogrel bisulfate therapy.26
The edge effect, described in association with stent-
based delivery systems, also has been noted to occur with
catheter-based systems and different isotopes. The uneven
distribution of radiation with edges receiving a smaller dose
compared with the therapeutic (and perhaps overtherapeu-
tic) center of delivery results in the edges expressing the
results of subtherapeutic radiation damage (proliferation)
and the core conferring overtherapy (thrombosis, tissue
damage). To date, no study has shown that the administra-
tion of vascular brachytherapy poses any undue risk to
patient or operator, yet broader based studies and longer
follow-up periods are necessary.
CLINICAL RESULTS
Peripheral vascular. The most common application
for the use of vascular brachytherapy in peripheral arteries is
the treatment of superficial femoral artery (SFA) lesions. A
list of the trials conducted for this application is displayed in
Table II. The initial studies examining the feasibility of
peripheral vascular brachytherapy were performed in
Frankfurt by Liermann et al27 and were conducted in 30
patients with in-stent restenosis of SFA. With the Micro-
Selectron-HDR system in a noncentered catheter, 30 pa-
tients first underwent atherectomy and PTA followed by
irradiation with Ir-192 for a total dose of 12 Gy, 3 mm into
the vessel wall. After a 7-year follow-up period, no adverse
effects were reported, and the 5-year patency rate was 82%,
with an 11% restenosis rate. Late occlusion occurred in two
of 28 patients (7%) after 16 months.
The effectiveness of the MicroSelectron system was
further investigated in a randomized, placebo-controlled
trial in Vienna with Ir-192 in a noncentering, close-end
lumen catheter delivering 12 Gy in 113 patients after
femoropopliteal PTA. Patients were followed at 6 and 12
months and showed a 54% restenosis rate in the PTA
group, whereas the group with PTA followed by irradiation
had a 6-month restenosis rate of 28% (P .013). A similar
50% difference in restenosis rate was observed at 12 months
(63% versus 35%).28 Moreover, the same group reported
on the effects of brachytherapy as prophylaxis against reste-
nosis in long segment femoropopliteal arteries undergoing
PTA and stent placement. In this study, 33 patients with
femoropopliteal lesions with a mean length of 17 cm un-
derwent PTA and stent implantation followed by Ir-192
delivered through a centered catheter to a total dose of 14
Arteriogram of SFA lesion (A) before angioplasty, (B) with PARIS catheter in place, and (C) after treatment at
6-month follow-up visit.
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Gy. They report a 6-month recurrence rate of 30% (10/33)
and a secondary (ie, after thrombolysis) patency rate of 88%
(29/33) at 6 months.29
In the United States, the first large-scale trial to exam-
ine the effect of -therapy on vascular stenosis was the
Peripheral Arterial Radiation Investigational Study (PAR-
IS), a Food and Drug Administration-approved, multi-
center, randomized, double-blind study. With a centered
segmental end lumen balloon catheter and the Micro-
Selectron-HDR afterloader, the primary endpoints of the
study were 6-month patency and restenosis rates and re-
duction of more than 30% of the treated lesions after
delivery of 14 Gy in conjunction with PTA of the SFA. In
addition, funtional patency was determined with treadmill
exercise testing and an ankle brachial index (ABI) improve-
ment of 0.1 compared with pre-PTA values. In the feasibil-
ity phase of PARIS, 40 patients with claudication were
enrolled. The mean lesion length was 9.9 3.0 cm, with a
mean reference vessel diameter of 5.4  0.5 mm. After
successful PTA, a segmented balloon-centering catheter
was positioned to cover the PTA site. The patients were
transported to the radiation oncology suite and treated
with radiation with a high dose rate MicroSelectron after-
loader. The isotope used for this study was Ir-192 (maxi-
mum of 10 Ci in activity), and the prescribed dose was 14
Gy to 2 mm into the vessel wall. ABI and maximum walking
time were evaluated with a repeat angiogram at 6 months.
Radiation was delivered successfully in all but two patients
because of technical difficulties. No procedural, in-hospital,
or 30-day complications occurred in any of the treated
patients. At 3 months, maximum walking time on treadmill
was increased from 3.56  2.7 minutes at baseline to
4.53  2.7 minutes (P  .01) and ABI was also improved
from 0.7  0.2 to 1.0  0.2. Among the first 20 patients
who returned for 5-month angiographic follow-up, only
one patient needed revascularization of the treated site. No
evidence has been found of arterial aneurysms or perfora-
tions. The 6-month angiographic follow-up was completed
on 30 patients; 13.3% of them had evidence of clinical
restenosis. The feasibility study of PARIS showed that the
delivery of a high dose rate -radiation via a centering
catheter is feasible and safe after PTA to SFA lesions.30 The
randomization phase for this study is scheduled to be
completed by early 2002.
Carotid brachytherapy. Just as the horizon of endo-
vascular treatment of carotid lesions is undergoing serious
consideration and attention, the use of brachytherapy in the
carotid position is largely experimental and in animal mod-
els. Wohlfrom and colleagues26 report on the diminutive
effects of Re-188 on postinjury neointimal hyperplasia in
the carotid arteries of hypercholesterolemic rabbits. A dose
of 15 Gy began to show reduction of the proliferative
response, whereas 45 Gy completely abolished the prolif-
erative response.31 A similar result was obtained by Sarac et
al,32 who showed a reduction in neointimal hyperplasia in
injured rat common carotid arteries with increasing doses
of -radiation. Compared with controls in animals at 3
weeks, a significant reduction was seen in neointimal hyper-
plasia in Ir-192 irradiated rats.32 Rubin et al33 showed an
attenuation of the proliferative response with radiation by
examining rat carotid artery subjected to balloon catheter
manipulation followed by increasing doses of radiation in
the form of externally placed Ir-192 to a maximum dose of
15 Gy. They showed a reduction in the amount of the
hyperplastic lesion up to 6 months after injury that was
concurrent with a demonstrated reduction in activated
macrophages/monocytes, further showing this cell popu-
lation to be the primary target of vascular brachytherapy.33
Dialysis access. The use of brachytherapy, both endo-
vascular and external beam, has been studied extensively as
a means to prolong/preserve patency of dialysis access.
Trerotola et al34 showed the effects of endoluminally deliv-
ered Ir-192 in five dogs with bilateral polytetrafluoroethyl-
ene dialysis access grafts. Each animal served as its own
control, outflow injury was obtained with placement of a
wall stent, and animals were followed for 10 months. They
showed a reduction in neointimal hyperplasia in irradiated
accesses.34
A pilot study was conducted at Emory University in
1994 to examine the effect of low dose radiation on neo-
intimal hyperplasia in patients with failed PTA of the ve-
nous outflow of dialysis access grafts. Patients were enrolled
if, after PTA, they had a 50% luminal stenosis. They first
underwent repeat PTA, followed by placement of a 5F
sheath across the lesion. Patients then were transported to
the radiation oncology suite where, with the Micro-
Selectron HDR afterloader, 14 Gy was delivered with high
activity Ir-192 source 2 mm into the arterial wall. Patients
Table II. Trials conducted
Study Enrolled Randomized
Centering
catheter
Dose
(Gy)
Distance
(mm) Patency rate
Frankfurt 30 – – 12 3 82%
Vienna 1 10 – – 12 3 60%
Vienna 2 113 Yes Yes 12 r  2 72%
Vienna 3 200 Yes Yes 18 r  2 –
Vienna 4 100 Yes Yes 14 r  2 –
Swiss 120 Yes – 12 r  2 72%
PARIS I 40 No Yes 14 r  2 87%
PARIS II 300 Yes Yes 14 r  2 –
r, Radius.
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were sent home after withdrawal of the catheter and were
followed with color flow Doppler scan bimonthly and
angiogram at 6 months. Eleven patients with 18 lesions
underwent treatment, and a 40% patency rate at 44 weeks
was reported.35 This study had many limitations, including
a limited patient population with already failed endovascu-
lar manipulation and some variability in the type of graft
treated and the actual dose of radiation delivered (7 to 90
Gy), and ultimately the results suggest that radiation ther-
apy did not alter outcome compared with PTA alone.
More recently, external beam therapy was examined as
a method of reducing restenosis in arteriovenous dialysis
grafts after angioplasty with or without stent placement.
The results, again on the basis of a small patient population,
showed no adverse effects of radiation exposure. However,
three of 10 patients had restenosis develop at the original
site, and one patient had a stenosis develop at the edge of a
stent. Five patients had de novo stenoses develop in proxi-
mal veins necessitating intervention,36 which concurred
with previous results obtained in the Emory pilot study.
Endovascular brachytherapy has been used successfully
in the treatment of failing Brescia-Cimino hemodialysis
fistulas,37 and external beam therapy continues to be inten-
sively investigated as a method for preventing postangio-
plasty restenosis of dialysis access. Although clearly feasible
with little adversity, the effect of radiation in significantly
preventing restenosis in dialysis access heretofore remains
inconclusive.20
Other peripheral vascular locations. Another pe-
ripheral application of vascular brachytherapy includes pre-
vention of restenosis of transjugular intrahepatic portosys-
temic shunts for patients with portal hypertension. These
shunts, which have a reported stenosis rate of as high as 70%
at 6 months and thrombosis as early as 2 weeks, may
significantly benefit from radiation therapy as a means of
supporting patency in this high risk group of patients.38
Anecdotal reports of endovascular brachytherapy of renal
artery stenosis39 and of treatment of central venous stric-
tures first treated with PTA can be found.40
CONCLUSION
Despite new technologies and devices, restenosis re-
mains the major limitation of intervention in the peripheral
vascular system. The results from preliminary studies show
that radiation in the form of vascular brachytherapy has the
potential to alter the rate of restenosis after intervention.
With the further progression of these studies and their
promising results, the use of vascular brachytherapy might
change the practice of peripheral intervention, resulting in
an improved long-term patency rate for our patients.
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